High-throughput biophysical analysis and data visualization of conformational stability of an IgG1 monoclonal antibody after deglycosylation.

The structural integrity and conformational stability of an IgG1 monoclonal antibody (mAb), after partial or complete enzymatic removal of the N-linked Fc glycan, were compared with the untreated mAb over a wide range of temperature (10°C-90°C) and solution pH (3-8) using circular dichroism, fluorescence spectroscopy, and static light scattering combined with data visualization employing empirical phase diagrams. Subtle-to-larger stability differences between the different glycoforms were observed. Improved detection of physical stability differences was then demonstrated over narrower pH range (4.0-6.0) using smaller temperature increments, especially when combined with an alternative data visualization method (radar plots). Differential scanning calorimetry and differential scanning fluorimetry were then utilized and also showed an improved ability to detect differences in the physical stability of a mAb glycoform. On the basis of these results, a two-step methodology was used in which conformational stability of a mAb glycoform is first screened with a wide variety of instruments and environmental stresses, followed by a second evaluation with optimally sensitive experimental conditions, analytical techniques, and data visualization methods. With this approach, a high-throughput biophysical analysis to assess relatively subtle conformational stability differences in protein glycoforms is demonstrated.

[1]  Jihun Lee,et al.  An empirical phase diagram approach to investigate conformational stability of “second‐generation” functional mutants of acidic fibroblast growth factor‐1 , 2012, Protein science : a publication of the Protein Society.

[2]  R. Ghirlando,et al.  Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. , 1999, Immunology letters.

[3]  B. Scallon,et al.  Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. , 2006, Biochemical and biophysical research communications.

[4]  C Russell Middaugh,et al.  Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: conformational stability and kinetic aggregation measurements. , 2012, Journal of pharmaceutical sciences.

[5]  Marcella Yu,et al.  Production, characterization and pharmacokinetic properties of antibodies with N-linked Mannose-5 glycans , 2012, mAbs.

[6]  G. Gilliland,et al.  Structure-based engineering of a monoclonal antibody for improved solubility. , 2010, Protein engineering, design & selection : PEDS.

[7]  David Ouellette,et al.  Increased serum clearance of oligomannose species present on a human IgG1 molecule , 2012, mAbs.

[8]  H. Gadgil,et al.  Evaluation of effects of Fc domain high-mannose glycan on antibody stability. , 2012, Journal of pharmaceutical sciences.

[9]  David B Volkin,et al.  Analytical lessons learned from selected therapeutic protein drug comparability studies. , 2013, Biologicals : journal of the International Association of Biological Standardization.

[10]  T. Veenstra,et al.  Engineered Human Antibody Constant Domains with Increased Stability* , 2009, Journal of Biological Chemistry.

[11]  R. Bayer,et al.  The impact of glycosylation on monoclonal antibody conformation and stability , 2011, mAbs.

[12]  C Russell Middaugh,et al.  Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. , 2012, Journal of pharmaceutical sciences.

[13]  Nathaniel R Maddux,et al.  An improved methodology for multidimensional high-throughput preformulation characterization of protein conformational stability. , 2012, Journal of pharmaceutical sciences.

[14]  G. Litman,et al.  Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. , 1987, The Journal of biological chemistry.

[15]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[16]  Santosh V. Thakkar,et al.  Comparison of the structural stability and dynamic properties of recombinant anthrax protective antigen and its 2-fluorohistidine-labeled analogue. , 2012, Journal of pharmaceutical sciences.

[17]  P. Bondarenko,et al.  High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. , 2011, Glycobiology.

[18]  C Russell Middaugh,et al.  Improved data visualization techniques for analyzing macromolecule structural changes , 2012, Protein science : a publication of the Protein Society.

[19]  Bill Pikounis,et al.  Comparability assessments of process and product changes made during development of two different monoclonal antibodies. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[20]  B. Müller-Tiemann,et al.  Generation and Comparative Characterization of Glycosylated and Aglycosylated Human IgG1 Antibodies , 2013, Molecular Biotechnology.

[21]  R. Jefferis Isotype and glycoform selection for antibody therapeutics. , 2012, Archives of biochemistry and biophysics.

[22]  Janice M. Reichert,et al.  Marketed therapeutic antibodies compendium , 2012, mAbs.

[23]  Anthony Mire-Sluis,et al.  Characterizing biological products and assessing comparability following manufacturing changes , 2004, Nature Biotechnology.

[24]  M Goodall,et al.  The influence of glycosylation on the thermal stability and effector function expression of human IgG1-Fc: properties of a series of truncated glycoforms. , 2000, Molecular immunology.

[25]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[26]  C Russell Middaugh,et al.  Biophysical characterization and stabilization of the recombinant albumin fusion protein sEphB4-HSA. , 2012, Journal of pharmaceutical sciences.

[27]  Effect of pH, temperature, and salt on the stability of Escherichia coli- and Chinese hamster ovary cell-derived IgG1 Fc. , 2012, Biochemistry.

[28]  R. Jefferis The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs , 2009, Biotechnology & genetic engineering reviews.

[29]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[30]  R. Huber,et al.  Structural analysis of human IgG-Fc glycoforms reveals a correlation between glycosylation and structural integrity. , 2003, Journal of molecular biology.

[31]  J. Reichert,et al.  Development trends for human monoclonal antibody therapeutics , 2010, Nature Reviews Drug Discovery.

[32]  M. Schenerman,et al.  Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. , 1999, Biologicals : journal of the International Association of Biological Standardization.

[33]  H. Sathish,et al.  Effects of salts from the Hofmeister series on the conformational stability, aggregation propensity, and local flexibility of an IgG1 monoclonal antibody. , 2013, Biochemistry.

[34]  J. Hochman,et al.  Pharmacokinetics of IgG1 monoclonal antibodies produced in humanized Pichia pastoris with specific glycoforms: a comparative study with CHO produced materials. , 2011, Biologicals : journal of the International Association of Biological Standardization.

[35]  R. Rustandi,et al.  Biochemical and biophysical characterization of humanized IgG1 produced in Pichia pastoris , 2011, mAbs.

[36]  C Russell Middaugh,et al.  Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry. , 2013, Journal of pharmaceutical sciences.

[37]  Bernhardt L Trout,et al.  Aggregation-prone motifs in human immunoglobulin G. , 2009, Journal of molecular biology.

[38]  Martin Schiestl,et al.  Acceptable changes in quality attributes of glycosylated biopharmaceuticals , 2011, Nature Biotechnology.

[39]  R. Jefferis,et al.  Interaction sites on human IgG-Fc for FcγR: current models , 2002 .

[40]  S. Jung,et al.  Revisiting the role of glycosylation in the structure of human IgG Fc. , 2012, ACS chemical biology.

[41]  A K Patel,et al.  The effect of the removal of sialic acid, galactose and total carbohydrate on the functional activity of Campath-1H. , 1995, Molecular immunology.

[42]  H. Gadgil,et al.  Elucidation of Acid-induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc , 2011, The Journal of Biological Chemistry.

[43]  Hongcheng Liu,et al.  Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. , 2006, Immunology letters.

[44]  B. Scallon,et al.  Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain , 2007, Biotechnology progress.

[45]  Gregory C Flynn,et al.  The effect of Fc glycan forms on human IgG2 antibody clearance in humans. , 2008, Glycobiology.

[46]  Hollis Lau,et al.  Acid-induced aggregation of human monoclonal IgG1 and IgG2: molecular mechanism and the effect of solution composition. , 2010, Biochemistry.

[47]  P. M. Buck,et al.  Impact of deglycosylation and thermal stress on conformational stability of a full length murine igG2a monoclonal antibody: Observations from molecular dynamics simulations , 2013, Proteins.

[48]  Yow-Ming C Wang,et al.  Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. , 2010, Trends in biotechnology.

[49]  S. Berkowitz,et al.  Characterization of IgG1 Conformation and Conformational Dynamics by Hydrogen/Deuterium Exchange Mass Spectrometry. , 2009, Analytical chemistry.

[50]  Damian Houde,et al.  Post-translational Modifications Differentially Affect IgG1 Conformation and Receptor Binding* , 2010, Molecular & Cellular Proteomics.

[51]  M. Schenerman,et al.  Advances in the assessment and control of the effector functions of therapeutic antibodies , 2011, Nature Reviews Drug Discovery.

[52]  S. Radaev,et al.  Recognition of IgG by Fcgamma receptor. The role of Fc glycosylation and the binding of peptide inhibitors. , 2001, The Journal of biological chemistry.

[53]  Kai Griebenow,et al.  Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.

[54]  Pauline M Rudd,et al.  The impact of glycosylation on the biological function and structure of human immunoglobulins. , 2007, Annual review of immunology.

[55]  Daniela Bumbaca,et al.  Physiochemical and Biochemical Factors Influencing the Pharmacokinetics of Antibody Therapeutics , 2012, The AAPS Journal.

[56]  Comparative signature diagrams to evaluate biophysical data for differences in protein structure across various formulations. , 2013, Journal of pharmaceutical sciences.

[57]  Kim Vo,et al.  Isolation and characterization of IgG1 with asymmetrical Fc glycosylation. , 2011, Glycobiology.

[58]  Bernhardt L Trout,et al.  Glycosylation influences on the aggregation propensity of therapeutic monoclonal antibodies. , 2011, Biotechnology journal.

[59]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.